NTLA 6001
Alternative Names: NTLA-6001Latest Information Update: 10 Jan 2023
At a glance
- Originator Intellia Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 05 Jan 2023 NTLA 6001 is available for licensing as of 05 Jan 2023. https://www.intelliatx.com/
- 02 May 2022 Pharmacodynamics data from preclinical studies in Lymphoma released by Intellia Therapeutics
- 28 Feb 2022 The US Patent and Trademark Office issues decision in favor of Broad Institute for interference claim for patent related to CRISPR-Cas9 genome editing technology in USA